Originally published In Press as doi:10.1074/jbc.M203176200 on August 14, 2002
J. Biol. Chem., Vol. 277, Issue 42, 39541-39547, October 18, 2002
Alkyl-lysophospholipid Accumulates in Lipid Rafts and Induces
Apoptosis via Raft-dependent Endocytosis and Inhibition of
Phosphatidylcholine Synthesis*
Arnold H.
van der Luit
,
Marianne
Budde
,
Paula
Ruurs
,
Marcel
Verheij
§, and
Wim J.
van Blitterswijk
¶
From the
Division of Cellular Biochemistry and the
§ Department of Radiotherapy, The Netherlands Cancer
Institute, 1066 CX Amsterdam, The Netherlands
Received for publication, April 3, 2002, and in revised form, August 14, 2002
 |
ABSTRACT |
The synthetic alkyl-lysophospholipid (ALP),
1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine,
is an antitumor agent that acts on cell membranes and can induce
apoptosis. We investigated how ALP is taken up by cells, how it affects
de novo biosynthesis of phosphatidylcholine (PC), and how
critical this is to initiate apoptosis. We compared an
ALP-sensitive mouse lymphoma cell line, S49, with an ALP-resistant
variant, S49AR. ALP inhibited PC synthesis at the
CTP:phosphocholine cytidylyltransferase (CT) step in S49 cells, but not
in S49AR cells. Exogenous lysophosphatidylcholine,
providing cells with an alternative way (acylation) to generate PC,
rescued cells from ALP-induced apoptosis, indicating that continuous
rapid PC turnover is essential for cell survival. Apoptosis induced by
other stimuli that do not target PC synthesis remained unaffected by
lysophosphatidylcholine. Using monensin, low temperature and albumin
back-extraction, we demonstrated that ALP is internalized by
endocytosis, a process defective in S49AR cells. This
defect neither involved clathrin-coated pit- nor fluid-phase
endocytosis, but depended on lipid rafts, because disruption of these
microdomains with methyl-
-cyclodextrin or filipin (sequestering
cholesterol) or bacterial sphingomyelinase reduced uptake of ALP.
Furthermore, ALP was found accumulated in isolated rafts and disruption
of rafts also prevented the inhibition of PC synthesis and apoptosis
induction in S49 cells. In summary, ALP is internalized by
raft-dependent endocytosis to inhibit PC synthesis, which
triggers apoptosis.
 |
INTRODUCTION |
The synthetic alkyl-lysophospholipid
(ALP),1
1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
(Et-18-OCH3; Edelfosine), is a selective antitumor agent,
known to induce apoptosis in various cell types (1, 2). Unlike
most conventional chemotherapeutic drugs, ALP does not target the DNA
but acts at the level of cell membranes. Because of its ether bonds ALP
is resistant to phospholipases, and therefore accumulates in the plasma
membrane as well as other subcellular membranes (3), where it inhibits
mitogenic and survival signaling pathways and activates the
stress-activated protein kinase/c-Jun NH2-terminal
kinase stress pathway (2, 4). The mechanism by which ALP affects
these pathways and induces apoptosis may relate to its disturbing
effect on lipid metabolism and lipid signaling in cell membranes
(5-7).
A major effect of ALP is the inhibition of de novo PC
synthesis (7). Several studies have suggested that maintenance of PC
biosynthesis is important for cell survival. A genetic defect in PC
biosynthesis induced apoptosis in Chinese hamster ovary cells (8),
whereas choline deficiency (via the culture medium) led to decreased PC
levels and induced apoptosis in PC12 cells and in primary neural
cultures (9, 10). PC biosynthesis occurs predominantly via the Kennedy
pathway in which the conversion of phosphocholine to CDP-choline,
catalyzed by CT, is the rate-limiting step, and the condensation of
CDP-choline with diacylglycerol by choline phosphotransferase
constitutes the final step. Inhibition of either of these enzymatic
steps may lead to apoptosis (11, 12).
In the present paper, we determined the effect of ALP on PC synthesis
in S49 mouse lymphoma cells, and found an inhibition at the CT step.
This enzyme resides in the nucleus and the cytoplasm and translocates
to the ER when activated (13). We questioned how ALP can reach this
intracellular target from outside the cell and how this subsequently
initiates apoptosis. There are reports on uptake of ALP correlating
with apoptosis induction (1, 14). However, the mechanism by which ALP
is internalized has remained uncertain. ALP is not taken up via a
specific receptor (such as for the structurally related
platelet-activating factor or lyso-PC) (1, 15-17). Some investigators
argue that endocytosis is not a major pathway by which ALP is taken up
(1, 14, 18), whereas others reach the opposite conclusion (15, 19). To
address this issue in more detail, we investigated the uptake and
action of ALP in S49 cells in comparison with an ALP-resistant variant cell line S49AR.
We report here that PC synthesis in S49AR cells remains
undisturbed because these cells are unable to internalize ALP as
efficiently as the parental cells. We provide evidence that ALP
concentrates in cholesterol- and sphingomyelin-rich membrane
microdomains, known as lipid rafts (20), that ALP is endocytosed via
intact rafts, and that reduced internalization of ALP in the
S49AR cells must be because of a defect in
raft-dependent endocytosis. Furthermore, we demonstrate
that the inhibition of PC biosynthesis in S49 cells depends on intact
rafts and is the direct trigger for initiation of apoptosis.
Maintenance of PC synthesis, for example, by providing the cell with an
alternative route of PC synthesis, is a factor that contributes to cell survival.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Methyl-[14C]choline chloride (58 mCi/mmol) was purchased from Amersham Biosciences.
[14C]Choline-lysoPC (LPC) (55 mCi/mmol) was purchased
from (American Radiolabeled Chemicals Inc., St. Louis, MO). ALP
was purchased from BioMol (Plymouth Meeting, PA).
[3H]Et-18-OCH3 ([3H]ALP; 58 Ci/mmol), was synthesized by Moravek Biochemicals (Brea, CA). Alexa-488
fluorescently labeled human transferrin and Sulforhodamine 101 were
purchased from Molecular Probes (Leiden, The Netherlands). Reagents for
lipid extraction and subsequent analyses, as well as Silica 60 TLC
plates (20 × 20 cm) were purchased from Merck (Darmstadt,
Germany). Cholera toxin B, rabbit anti-cholera toxin B,
sphingomyelinase (Bacillus cereus), filipin, and
M
CD were purchased from Sigma (Zwijndrecht, The Netherlands) and the
peroxidase-conjugated swine anti-rabbit Ig was obtained from DAKO A/S
(Glostrup, Denmark).
Cells Cultures--
Mouse S49.1 lymphoma cells (S49) were grown
in Dulbecco's modified Eagle's medium, supplemented with 8% fetal
calf serum, 2 mM L-glutamine, 100 units/ml
penicillin, 100 µg/ml streptomycin at 37 °C and 5%
CO2. ALP-resistant variants (S49AR) were
isolated in two selection rounds of growth in 15 µM ALP (Et-18-OCH3) for 72 h, followed by plating in
semisolid medium and isolation of colonies of surviving cells, as
described by Smets et al. (21). The selective
S49AR clone could be grown continuously in 15 µM ALP with a doubling time of 12 h, similar to that
of the parent S49 cells. All experiments with S49AR cells
were performed with cells grown without the selection agent for at
least 1 week.
Apoptosis Assay--
Cells were seeded at 1.5 × 106 cells/ml, cultured overnight, and incubated for the
indicated time periods with various concentrations of
Et-18-OCH3 (ALP). Cells were washed in phosphate-buffered
saline (PBS) and lysed overnight at 4 °C in 0.1% (w/v) sodium
citrate, 0.1% (v/v) Triton X-100, and 50 µg/ml propidium iodide
(22). Fluorescence intensity of propidium iodide-stained DNA was
determined on a FACScan (BD Biosciences), and data were analyzed
using Lysis software.
ALP Uptake--
Cells were grown to a density of 2.5 × 106/ml and ALP was added in the apoptotic concentration of
15 µM, supplemented with 0.2 µCi of
[3H]ALP/ml. At given time points samples were taken
followed by a 2-min incubation on ice and three washes with cold PBS.
Samples were lysed in 0.1 N NaOH for scintillation
counting. Back-extraction of ALP was performed by washing the cells
with PBS containing 1% (w/v) fatty acid-free BSA.
Endocytosis--
Cells were grown to a density of 2.5 × 106/ml and incubated for 30 min with Alexa-488
fluorescently labeled human transferrin (1 µg/ml) or with the
fluorescent fluid-phase marker, Sulforhodamine 101 (25 µg/ml).
Endocytosis of these compounds was stopped on ice. Cells were washed
thoroughly with cold PBS and the fluorescence measured by FACScan
analysis (BD Biosciences). Data were analyzed using FCS express software.
PC Biosynthesis Using [14C]Choline or
[14C]LPC--
Cells at 2.5 × 106
cells/ml were incubated with
[methyl-14C]choline chloride (1 µCi/ml) or
[14C]LPC (0.1 µCi/ml). At the given time points,
aliquots of cells were taken, washed, and resuspended in 200 µl of
PBS. Lipids were extracted with chloroform/methanol (1:2, v/v) and
phase separation was induced using 1 M NaCl. The organic
phase was washed in a solution of methanol/H2O/chloroform
(235:245:15, v/v/v), and separated by silica TLC, using
chloroform/methanol/acetic acid/water (60:30:8:5, v/v/v/v). Radioactive
lipids were visualized and quantified using a Fuji BAS 2000 TR
PhosphorImager and identified using internal standards, which were
visualized by iodine staining.
Isolation of Lipid Rafts--
A lipid raft fraction was prepared
by detergent extraction of cells and sucrose gradient centrifugation,
essentially as described (23). Cells were grown to a density of
2.0 × 106/ml, spun down, and washed with 2× 10 ml of
ice-cold phosphate-buffered saline. Cells were solubilized into 2 ml of
ice-cold MBST buffer (25 mM MES, 150 mM NaCl,
1% Triton X-100, 1 mM Pefabloc) and homogenized with a
loose fitting Dounce homogenizer (10 strokes). The extract was adjusted
to 40% sucrose by the addition of 2 ml of 80% sucrose in MBS (lacking
Triton X-100) and put on the bottom of an ultracentrifuge tube. A
discontinuous sucrose gradient was prepared by overlaying 5 ml of 40%
sucrose and 3 ml of 5% sucrose (both in MBS), respectively. The tubes
were centrifuged at 39,000 rpm in a SW41 rotor for 16-18 h at 4 °C
and 12× 1.0-ml fractions were collected manually from the top of the
gradient. For incorporation of ALP in lipid rafts, cells were
incubated with [3H]Et-18-OCH3 (ALP; 0.2 µCi/ml; 15 µM) for 5 min to allow insertion into the
outer leaflet of the plasma membrane lipid bilayer.
Analysis of Raft Markers, Sphingomyelin and
GM1--
Sphingomyelin levels in each fraction were determined after
24 h radiolabeling with 1 µCi/ml
[methyl-14C]choline-HCl, after Triton X-100
solubilization and sucrose gradient centrifugation followed by TLC
separation (system, see above). The ganglioside, GM1, level in each
fraction was determined by a dot-blot technique using cholera toxin B
binding. In short, 2.5 µl of each sucrose gradient fraction was
spotted onto a nitrocellulose membrane, air-dried, and washed with PBS.
Membranes were blocked with 3% (w/v) BSA in PBS, and incubated with 1 µg/ml cholera toxin B for 30 min at 4 °C. Blots were washed and
incubated with rabbit anticholera toxin B in a 1:500 dilution and
followed by an incubation at room temperature with horseradish
peroxidase-conjugated swine anti-rabbit Ig (1:7500). Spots were
visualized by chemiluminescence using the Amersham ECL kit according to
the manufacturer's instructions.
 |
RESULTS |
ALP Induces Apoptosis in S49 Lymphoma Cells; S49AR
Cells Are Resistant to ALP--
The synthetic ether lipid
Et-18-OCH3 (Edelfosine; ALP) induces apoptosis in S49 cells
in a dose-dependent fashion, with an EC50 of
about 12 µM (Fig. 1,
A and B). The onset of apoptosis in the S49 cell
population was already apparent after 3 h. Apoptosis was maximal
(80%) at 7 h, whereas half-maximal values were reached after
4 h (data not shown). The ALP-resistant variant S49AR
did not undergo apoptosis during the time period of the experiment and at the ALP concentration range tested (Fig. 1A).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 1.
ALP-induced apoptosis in S49 cells,
suppressed by exogenous lyso-PC. A, ALP-sensitive
S49 cells ( ) and ALP-resistant S49AR cells ( ) were
treated with Et-18-OCH3 (ALP; concentrations indicated) for
4 h. Apoptotic nuclear fragmentation was measured by FACScan
analysis (see "Experimental Procedures" and below). Data are means
of four experiments ± S.D. B, ALP-induced
apoptosis in S49 cells, visualized as nuclear fragmentation (appearance
of the subdiploid peak in front of the G1/S/G2
doublet peak) after propidium iodide staining and FACScan analysis.
Co-addition of lyso-PC (25 µM) prevents ALP (15 µM)-induced apoptosis. C, dose dependence
of the inhibition of ALP (15 µM)-induced apoptosis in S49
cells by LPC (black bars); apoptosis was scored by
FACScan analysis (as in panel B) after 4 h of
incubation. White bars, controls with LPC alone. Data are
means of three experiments ± S.D.
|
|
ALP Inhibits PC Synthesis at the Level of Cytidylyltransferase in
S49 Cells, but Not in S49AR Cells--
To understand how
ALP induces apoptosis in S49 cells and why S49AR cells are
resistant, we followed the suggestion that ALP would inhibit the
de novo synthesis of PC (7). Using
[14C]choline pulse-chase labeling, we found that ALP
blocks [14C]choline incorporation into the PC and
CDP-choline pools in S49 cells, but virtually not in S49AR
cells (data not shown). ALP had virtually no effect on
[14C]phosphocholine levels. These results are consistent
with the notion that ALP inhibits the rate-determining enzyme in the
Kennedy pathway of PC synthesis, CT (7). Contrary to S49 cells, this enzyme does not appear to be a target of ALP in the resistant S49AR variant.
Lyso-PC Addition Prevents ALP-induced Apoptosis--
Because
apoptosis induction by ALP correlated with inhibition of de
novo PC synthesis, we questioned whether this lack of newly
generated PC is the direct trigger that initiates the apoptotic machinery. To test this, we provided the cell with an alternative way
to generate PC, that is by adding LPC via the culture medium. LPC,
structurally related to ALP, readily incorporates in the plasma
membrane and is very rapidly acylated to PC in S49 cells (Fig.
2), but notably much slower in
S49AR cells. (The latter is of interest, and may be because
of reduced endocytic uptake of LPC, as will be clarified below.) ALP
has no effect on the rate of LPC acylation. Fig. 1B shows
the effect of exogenous LPC on ALP-induced apoptosis. In the Nicoletti
(FACScan) apoptosis assay (22), ALP induces the appearance of a
subdiploid peak of nuclear fragments (Fig. 1B). Addition of
LPC (25 µM) prevents the formation of this apoptotic
population. Of note, ALP with or without LPC does not change the
distribution among G1/S/G2 of the cell cycle,
which is at variance with published data in a different cell system
(24). Fig. 1C shows that LPC rescues S49 cells from
ALP-induced apoptosis in a dose-dependent fashion, with 25 µM being the most effective concentration. This effect of
LPC is specific for ALP-induced apoptosis, because apoptosis induced by
other treatments (etoposide and
-radiation) remained unaffected by
the addition of LPC (data not shown). Unlike ALP, these treatments had
no effect on PC synthesis (data not shown).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 2.
Conversion of exogenous lyso-PC to cellular
PC. Kinetics of acylation of exogenous [14C]lyso-PC
to [14C]PC, in the presence (open symbols) or
absence (closed symbols) of 15 µM ALP, in S49
cells (upper panel) and S49AR cells (lower
panel). Data are percentages of 14C incorporation into
the cellular lipid pools (LPC and PC add up to 100%). Symbols:
squares, LPC; circles, PC. Data represent the
means of two independent experiments.
|
|
From these observations we conclude that inhibition of PC synthesis is
sufficient to induce apoptosis, and that continual, unimpeded PC
synthesis/turnover is important for cell survival. LPC, through
conversion to cellular PC, alleviates ALP inhibition of PC synthesis
and consequently rescues cells from ALP-induced apoptosis. LPC does not
affect apoptosis induced by agents that have no direct effect on PC turnover.
ALP Is Rapidly Internalized in S49 Cells, but Internalization in
S49AR Cells Is Impaired--
CT, the target of ALP, is
known to reside in the endoplasmic reticulum and the nucleus (13). We
therefore addressed the questions how ALP is internalized in S49 cells
and if the resistance of S49AR cells might be because of
their inability to internalize the ether lipid. Fig.
3 shows that, in time, the uptake of
radiolabeled ALP in the S49AR cells was considerably less
than in S49 cells. Initially, the two cell types bound the same amount
of label. However, after 30 min the uptake of ALP leveled off in
S49AR cells but not in S49 cells. Because the uptake of ALP
in S49 cells does not reach saturation, it is unlikely that it would be
mediated by a receptor (like that for PAF), which agrees with other
reports (1, 15, 17). Instead, we envision that ALP, because of its
single long alkyl chain, easily inserts into the outer leaflet of the
plasma membrane lipid bilayer, prior to and/or during internalization.
Employing the strong binding of ALP to albumin, we determined with
albumin back-extraction (25) the fraction of [3H]ALP that
remained located in this outer leaflet, and how much was internalized
in time. Fig. 3 shows that, initially, most of the
[3H]ALP associated to S49AR cells could be
back-extracted by albumin, particularly during the first 30 min (this
is also shown in an alternative way in the inset of Fig. 3).
In contrast, in S49 cells, the majority of ALP remained cell-associated
after back-extraction at all times, indicating that, in these cells,
ALP is rapidly internalized. Interestingly in this respect, exogenous
LPC (being structurally similar to ALP) is only slowly converted to PC
in S49AR cells compared with S49 cells (Fig. 2), suggesting
that S49AR cells, which show reduced ALP internalization,
likewise show a reduced LPC internalization. Of note, ALP does not
affect LPC uptake (conversion to PC; Fig. 2). The same holds for the
reverse: addition of LPC does not affect the uptake of ALP by the cells (data not shown). We conclude that addition of ALP to S49 cells leads
to its almost instantaneous internalization, in contrast to
S49AR cells where ALP internalization is significantly
delayed and occurs in lower amounts.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 3.
Uptake of radiolabeled ALP by S49 and
ALP-resistant S49AR cells; effect of BSA
back-extraction. Persistent ALP association to cells following BSA
back-extraction is represented by the open symbols. ALP
uptake in S49 without ( ) or with BSA back-extraction ( ); ALP
uptake in S49AR without ( ) or with BSA back-extraction
( ). Data are given in [3H]ALP radioactivity
(disintegrations/min) bound per 103 cells, and represent
the averages of four experiments (absence of error bars
means that the S.D. value is within the size of the symbol).
Inset, percentage of ALP back-extractable by BSA from S49
cells ( ) and from S49AR cells ( ).
|
|
Apoptosis Induction by ALP Requires Its Endocytosis--
We next
addressed the question how this rapid internalization in S49 cells
occurs. Basically, two mechanisms could be envisioned: (a)
passive diffusion involving plasma membrane transbilayer movement (flip-flop), which is unlikely because it is a relatively slow process
(26), at least when it occurs spontaneously; (b) via formation, budding off, and intracellular release of membrane vesicles
from the plasma membrane, i.e. endocytosis. We tested the
latter, a more likely mechanism by two different ways to block endocytosis. First, cells were kept at 4 °C. Indeed, an ~80%
reduced uptake of ALP was observed in S49 cells during a 2-h time
period (data not shown). In the cold, the amount of ALP associated to S49 cells was the same as to the S49AR cells. Moreover,
under these conditions the same amount (about 90%) of ALP could be
back-extracted from these cells by albumin (data not shown), indicative
of the same outer leaflet plasma membrane location of ALP in the two
cell types in the cold. Therefore, the difference of (nonextractable)
ALP retention seen in Fig. 3 (first 30 min at 37 °C) between the two
cell types is likely to be ascribed to endocytosis in the S49 cells.
The second way by which we blocked endocytosis was with monensin, which
acts via altering membrane electropotential and pH (27). Also this treatment reduced ALP uptake in S49 cells (~50%), reaching the low
level of uptake in the S49AR cells (Fig.
4A). Uptake in
S49AR cells was not further affected by monensin,
suggesting that the low level of ALP internalization in these resistant
cells does not occur via endocytosis (at least not sensitive to
monensin), but possibly via transbilayer movement. Importantly,
monensin blocks ALP-induced apoptosis of S49 cells in a
dose-dependent fashion (Fig. 4B), which further
supports the notion that monensin, through inhibition of endocytosis,
prevents ALP to reach its target (CT) in the ER for initiation of
apoptosis. Together, these results strongly suggest that in S49 cells,
ALP is taken up by endocytosis, whereas in S49AR cells,
endocytosis of ALP is impaired.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 4.
Restrained ALP uptake in the presence of
monensin (A) prevents apoptosis
(B). A, uptake of
[3H]ALP (15 µM; 0.2 µCi; 37 °C) by S49
cells (circles) and S49AR cells
(squares) as a function of time, in the absence (solid
symbols) and presence (open symbols) of 5 µM monensin. B, S49 cells were treated
with the indicated concentrations of monensin (black bars),
added 30 min prior to ALP (15 µM). Apoptosis was
determined as nuclear fragmentation, measured by FACScan analysis.
Open bars, controls with monensin alone. Data are mean ± S.D. of three experiments.
|
|
Cells can make use of clathrin-dependent or -independent
routes of endocytosis, for signal transduction or uptake of nutrients. Fig. 5 (upper panel) shows
that the ALP-resistant S49AR cells have normal
receptor-mediated uptake of (fluorescent) transferrin, known to occur
via clathrin-coated pits. Also the uptake of Sulforhodamine 101, a
fluorescent marker for clathrin-independent fluid-phase endocytosis,
does not differ between S49 and S49AR cells (Fig. 5,
lower panel). Thus, the difference in ALP uptake between the
two cell types must be because of a different mechanism of endocytosis.
Therefore, we tested another clathrin-independent route of endocytosis,
more recently discovered, that is via lipid rafts (28-30).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 5.
Transferrin receptor (TrR)
and fluid phase-mediated endocytosis in S49AR cells do not
differ from S49 cells. Cells were incubated for 30 min with
Alexa-488 fluorescently labeled human transferrin (1 µg/ml;
upper panel) or with the fluorescent fluid-phase marker,
Sulforhodamine 101 (25 µg/ml; lower panel), and the uptake
of fluorescence is shown by FACScan analysis (gray profile,
relative to autofluorescence control).
|
|
ALP Partitions in Lipid Rafts--
Based on its structure, with an
ether bond and a single saturated alkyl chain, ALP
(Et-18-OCH3) is predicted to accommodate to the rigid,
sphingolipid- and cholesterol-enriched membrane rafts (31, 32). We
tested this directly by isolation of rafts using the well established
method of Triton X-100 solubilization and sucrose density gradient
centrifugation (23) (Fig. 6). When cells
were incubated with radiolabeled ALP for 5 min, most of the ether lipid
was found accumulated in raft fractions 3 and 4 (Fig. 6C),
and in equal amounts for S49 and S49AR cells. ALP
co-distributed with the typical raft marker sphingomyelin (Fig.
6A). Another raft marker, the ganglioside GM1, visualized by
cholera toxin B labeling using a dot-blot technique (Fig.
6B), accumulated in the same region of the gradient albeit
consistently at a slightly higher density. Disruption of rafts by
treatment of cells with M
CD, which extracts cholesterol, resulted in
the redistribution of GM1 and ALP to non-raft fractions (Fig. 6,
B and D).

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 6.
ALP accumulates in lipid rafts, both in S49
and S49AR cells; disturbance by
M CD pretreatment. Lipid rafts from S49 or
S49AR cells were isolated by sucrose density gradient
centrifugation. A, raft marker sphingomyelin
(SM), visualized by [14C]choline labeling and
PhosphorImaging after TLC separation. B, raft marker GM1,
visualized by cholera toxin B binding and immunoblotting of gradient
fractions of S49 cells spotted on nitrocellulose filters (upper
panel), and quantified by densitometry (A.U., arbitrary
units) (lower panel). Effect of disruption of lipid rafts by
pretreatment of S49 cells for 30 min with M CD (5 mg/ml) (lower
series of spots, open bars), versus control cells
(upper series of spots, black bars).
C, distribution of [3H]ALP (15 µM; 0.2 µCi), expressed in disintegrations/min per 1-ml
fraction from equal numbers of S49 cells (closed circles)
and S49AR cells (squares). D,
distribution [3H]ALP over the gradient fractions, without
(closed circles) or with prior disruption of lipid rafts in
S49 cells by M CD (squares), as in panel B.
Data are representative of two independent experiments.
|
|
Endocytosis of ALP, Inhibition of PC Synthesis, and Subsequent
Apoptosis Depend on Intact Rafts--
From the data so far, we have
concluded that ALP, after insertion into the plasma membrane, reaches
its intracellular target, CT, by an endocytotic mechanism that does not
involve clathrin-coated pits nor fluid-phase endocytosis. Because ALP
accumulates in lipid rafts, we tested the involvement of these
microdomains in the endocytic uptake of ALP by disrupting the rafts in
three different ways. First, by M
CD, which extracts cholesterol;
second, by filipin, which forms lateral complexes with cholesterol
within the membrane; third, with bacterial sphingomyelinase, which
hydrolyzes the major raft component sphingomyelin (33). Each treatment
abrogated to different extents the capability of S49 cells to take up
ALP (Fig. 7, at 120 min), without causing
plasma membrane leakage (as determined by the lack of trypan blue
uptake) or altering cell morphology (controls not shown). Fig. 7 also
shows that the initial binding of ALP to the plasma membrane, measured
at 10 min, was not affected by raft disruption. Although this
disruption caused a partial displacement of ALP of the rafts (Fig.
6D), the overall initial binding of ALP to the plasma
membrane remained the same. Only the subsequent cellular uptake through
internalization was blocked by the raft disruption.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 7.
Disruption of lipid rafts prevents ALP uptake
in S49 cells. S49 and S49AR cells were treated for 30 min with M CD (1 mg/ml), filipin (1 µg/ml), bacterial
sphingomyelinase (150 milliunits/ml; from B. cereus), or
control medium, as indicated in the figure legend, and the amount of
[3H]ALP uptake was determined at 10 and 120 min. Data are
expressed in disintegrations/min per 103 cells and are
averages ± S.D. of three experiments.
|
|
We next tested whether raft disruption abrogated the inhibitory action
of ALP on the de novo synthesis of PC and the induction of
apoptosis. Fig. 8A shows, in
S49 cells, the time-dependent incorporation of
[14C]choline into PC, which is 50% inhibited by ALP.
This inhibition of PC synthesis is prevented by prior disruption of
lipid rafts by bacterial sphingomyelinase or M
CD. These treatments
alone did not affect PC synthesis (controls not shown). Fig.
8B shows that raft disruption by M
CD prevents ALP-induced
apoptosis in a dose-dependent manner.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 8.
Disruption of lipid rafts alleviates ALP
inhibition of de novo PC biosynthesis and prevents
apoptosis in S49 cells. A, cells were preincubated
with ALP (15 µM) for 15 min before
[14C]choline incorporation into PC for the time periods
indicated. Lipid rafts were disrupted by M CD (1 mg/ml) or bacterial
sphingomyelinase (bSMase, from B. cereus; 150 milliunits/ml) added 30 min before ALP. Values are in
14C-arbitrary (PhosphorImager) units. B,
various doses of M CD (black bars) were added 30 min prior
to ALP (15 µM). Apoptosis was determined as nuclear
fragmentation, measured by FACScan analysis. Open bars,
controls with M CD alone. Data are mean ± S.D. of three
experiments.
|
|
We thus conclude that intact rafts are required for the endocytic
uptake of ALP by S49 cells, and the subsequent inhibition of PC
synthesis that leads to the induction of apoptosis. Given that ALP
partitions equally well in the raft fraction of S49AR cells
(Fig. 6C), it remains to be investigated why rafts in these cells do not mediate ALP internalization.
 |
DISCUSSION |
In this paper, we have shown that apoptosis induction by ALP
requires its endocytosis, depending on intact lipid rafts, to inhibit
de novo biosynthesis of PC at the level of CT inside the cell. Because an alternative pathway of PC synthesis, i.e.
the acylation of exogenous LPC, alleviates shortage of newly produced PC and rescues cells from apoptosis induction, we conclude that impaired PC synthesis is the direct trigger of ALP-induced apoptosis. In other words, PC synthesis is a survival factor in this cell system.
Consistent with this notion, apoptosis induced by other treatments,
such as ionizing radiation, which acts predominantly by damaging DNA
but does not affect PC synthesis, was found not counteracted by
exogenous LPC (data not shown). Results by Jackowski and co-workers (7,
11) likewise point to PC synthesis as a survival factor in different
cell systems. However, their results differ from our findings with
respect to the cell cycle. In BAC1.2F5 macrophage-like cells, ALP
caused a cell cycle arrest (accumulation in the G2/M
phase), which was overcome by LPC (24), whereas our FACScan analysis in
S49 cells did not show altered cell-cycle distribution by ALP or LPC in
Fig. 1B. Apparently, these effects are cell
type-dependent.
We have demonstrated, by albumin back-extraction of ALP and by low
temperature and monensin treatment of S49 cells, that ALP is
internalized by endocytosis, and that this internalization is impaired
in the resistant S49AR cells. In this way,
S49AR cells escape from the deleterious action of ALP. We
have confirmed in a different cell system (HeLa) that internalization
of ALP is dependent on the GTPase dynamin, a mediator of endocytosis (34-36). A dominant-negative mutant of dynamin blocked ALP
internalization in these HeLa
cells.2 Plasma membrane
lipids can be endocytosed both in a clathrin-dependent and
-independent fashion (29). The latter route occurs ubiquitously and
constitutively, and plays an important role in rapid membrane recycling
or remodeling of the plasma membrane and the formation of lipid second
messengers in response to external stimuli (30). This route of
endocytosis is, for example, also used by exogenous fluorescent
membrane-permeable lipids (29, 37, 38). It is therefore not entirely
unexpected, but was hitherto never shown that membrane-incorporated ALP
is internalized in the same way.
One clathrin-independent way of endocytosis depends on lipid
rafts/caveolae (28, 30, 39). Ligands as well as membrane lipid
constituents (probably as entire rafts, clustered or not) can be
internalized in this way. For example, the B subunit of cholera toxin,
after binding to a typical raft lipid, GM1, is internalized in part
directly via these microdomains in a dynamin-mediated fashion (35, 36,
40) (although the proportion that is internalized via this route may
depend on the cell type) (41). Also, internalization of interleukin-2
by its receptor (42) and entry of pathogens (bacteria, viruses, etc.)
(43, 44) occurs via lipid rafts.
Being enriched in sphingolipids and cholesterol, membrane rafts have a
high degree of lipid structural order (high rigidity; low fluidity
(32)). Based on its structure, with an ether bond and a single, long
saturated alkyl chain, ALP will easily accommodate to these rigid
microdomains (31, 32), as we have demonstrated here by isolating lipid
rafts on a sucrose density gradient, using sphingomyelin and GM1 as
genuine raft markers. ALP was found enriched in rafts, and in equal
quantities in S49 and S49AR cells (Fig. 6C). In
S49, but not in S49AR cells, ALP is rapidly internalized
presumable as the molecular component of the constitutive raft-mediated
endocytosis (which is impaired in S49AR cells). Disruption
of rafts in three different ways, i.e. treatment with
M
CD, filipin, or bacterial sphingomyelinase, prevented ALP internalization in the S49 cells. Furthermore, we demonstrated that ALP
partitioning in rafts, a rapid event (within 5 min), was disturbed by
M
CD pretreatment, resulting in a redistribution of ALP to nonraft
fractions without altering the initial overall binding to the plasma
membrane (Figs. 6D and 7).
The defect in S49AR cells to internalize ALP appeared
unrelated to clathrin-coated pit-mediated or fluid-phase endocytosis, because the uptake of transferrin (via clathrin-coated pits) and a
fluid phase marker were the same as in the S49 cells. These classical
routes of endocytosis are usually directed toward late endosomes/lysosomes, whereas raft-mediated endocytosis does not target
the lysosomes but is directed toward a rapid cycling pathway, via the
Golgi or the ER back to the plasma membrane (28-30). This route may
contribute to regulate protein/lipid sorting and trafficking (45).
Accordingly, ALP is likely to follow such a pathway to inhibit CT in
the ER. We have provided direct evidence for this notion; disruption of
lipid rafts by M
CD or bacterial sphingomyelin prevented ALP
inhibition of PC biosynthesis (Fig. 8).
Raft-mediated endocytosis and associated vesicular traffic is thus an
active continuous cellular process (29, 38). We have demonstrated, by
ALP uptake and albumin back-extraction data (Figs. 3, 4, and 7), that
this process is disrupted in the ALP-resistant S49AR cells.
However, the molecular details of this defect remain to be resolved. We
showed that the amount of ALP initially (first 30 min) bound to S49 and
S49AR cells is the same (Fig. 3) and that ALP partitions
equally well in the raft fraction of the two cell types (Fig.
6C). Apparently, another property of the rafts, their
molecular composition, and/or their functional dynamics is defective in
the resistant cell. Preliminary data suggest a decreased sphingomyelin
content in these cells (46) but this needs extensive further
elaboration, and is subject of our current investigations.
The conclusion that new, unrestrained PC synthesis is important for
cell survival raises the question, why? Not because PC is required for
membrane expansion, which is only relevant for cell proliferation, but
presumably because this PC synthesis is needed to replenish the
continuous and rapid PC breakdown by phospholipases, types A2, C, and
D, to generate the respective second messengers, arachidonate (and
further metabolites), diacylglycerol, and phosphatidic acid, for
different signaling purposes (47, 48). In addition, (new) PC is needed
for Golgi-localized synthesis of sphingomyelin and diacylglycerol, both
of which are involved in signal transduction as well (49, 50). At least
some of these rapid conversions (turnover) of PC are believed to occur
at/near the plasma membrane or, more likely, in (recycling) endosomes
(51), which have recently been appreciated as sites of signal
transduction (52). Moreover, there is intriguing evidence suggesting
that PC biosynthesis may be regulated in response to the lipid
requirements of vesicular trafficking (13, 50, 53). We have previously
shown that exogenous LPC, which rescues cells from ALP-induced
apoptosis, is first internalized before it is acylated to PC (54). This internalization most probably occurs via endocytosis, because LPC
uptake and conversion to PC is severely hampered in the
S49AR cells (Fig. 2) that, likewise, are impaired to
internalize (by endocytosis) the structurally related ALP (Fig. 3).
Thus, the compartment where PC is continuously degraded and where new
PC is thus needed, is probably the same one where LPC is converted to
PC, likely an endosomal compartment. We therefore speculate that the
trigger that initiates apoptosis may actually be located in this
endosomal compartment. If de novo synthesis of PC
exclusively occurs in the ER (which is not certain), it is conceivable
that this newly made PC merges, through vesicular trafficking or a PC
transfer protein, with this endosomal compartment (13, 50, 53).
We have argued (see "Results") that the very rapid internalization
of ALP and LPC in S49 cells (Figs. 2 and 3) is not likely explained by
transbilayer movement (flip-flop) because this process is too slow.
Yet, at some stage these lipids must adopt an altered orientation,
because their respective "target" enzymes, CT and acyltransferase that would yield PC, are thought to operate at the
cytosolic side of the ER or endosome. Most likely, the extensive and
rapid fusion-fission events during vesicular traffic associated with
lamellar-to-hexagonal phase transitions and loss of asymmetry of the
membrane phospholipids may suffice to expose these lysophospholipids to
their target enzymes.
To conclude, synthetic ether lipids such as Et-18-OCH3
(ALP) are new potential cancer therapeutics that, unlike classical cytotoxic drugs, act on membranes and particularly inhibit PC synthesis
at the CT step. To be effective, ALP must be endocytosed and utilizes,
for this purpose, lipid rafts as selective portals in the plasma
membrane to enter the cell. The selectivity of ALP to kill cancer cells
(by apoptosis) presumably relates to their high metabolic activity
associated with extensive raft-mediated endosomal vesicular traffic.
Lipid rafts may thus be a potential therapeutic target not previously
considered in cancer research.
 |
ACKNOWLEDGEMENTS |
We thank Eric Nooteboom and Anita Pfauth
for their assistance in FACScan analysis and Robert Jan Veldman for
useful suggestions on lipid raft isolation.
 |
FOOTNOTES |
*
This work was supported by Dutch Cancer Society Grant NKI
99-2047.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Division of
Cellular Biochemistry, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel.: 31-20-5121976; Fax:
31-20-5121989; E-mail: w.v.blitterswijk@nki.nl.
Published, JBC Papers in Press, August 14, 2002, DOI 10.1074/jbc.M203176200
2
A. H. Van der Luit, M. Budde, M. Verheij,
and W. J. Van Blitterswijk, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
ALP, alkyl-lysophospholipid;
AR, ALP resistance;
BSA, bovine serum albumin;
CT, CTP:phosphocholine cytidylyltransferase;
Et-18-OCH3, 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine;
LPC, lysophosphatidylcholine;
ER, endoplasmic reticulum. M
CD,
methyl-
-cyclodextrin;
PC, phosphatidylcholine;
MES, 4-morpholineethanesulfonic acid;
PBS, phosphate-buffered saline.
 |
REFERENCES |
| 1.
|
Mollinedo, F.,
Fernandez-Luna, J. L.,
Gajate, C.,
Martin-Martin, B.,
Benito, A.,
Martinez-Dalmau, R.,
and Modolell, M.
(1997)
Cancer Res.
57,
1320-1328[Abstract/Free Full Text]
|
| 2.
|
Ruiter, G. A.,
Zerp, S. F.,
Bartelink, H.,
van Blitterswijk, W. J.,
and Verheij, M.
(1999)
Cancer Res.
59,
2457-2463[Abstract/Free Full Text]
|
| 3.
|
van Blitterswijk, W. J.,
Hilkmann, H.,
and Storme, G. A.
(1987)
Lipids
22,
820-823[Medline]
[Order article via Infotrieve]
|
| 4.
|
Ruiter, G. A.,
Verheij, M.,
Zerp, S. F.,
and van Blitterswijk, W. J.
(2001)
Int. J. Radiat. Oncol. Biol. Phys.
49,
415-419[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Powis, G.,
Seewald, M. J.,
Gratas, C.,
Melder, D.,
Riebow, J.,
and Modest, E. J.
(1992)
Cancer Res.
52,
2835-2840[Abstract/Free Full Text]
|
| 6.
|
Zhou, X.,
and Arthur, G.
(1995)
Eur. J. Biochem.
232,
881-888[Medline]
[Order article via Infotrieve]
|
| 7.
|
Boggs, K. P.,
Rock, C. O.,
and Jackowski, S.
(1995)
J. Biol. Chem.
270,
7757-7764[Abstract/Free Full Text]
|
| 8.
|
Cui, Z.,
Houweling, M.,
Chen, M. H.,
Record, M.,
Chap, H.,
Vance, D. E.,
and Terce, F.
(1996)
J. Biol. Chem.
271,
14668-14671[Abstract/Free Full Text]
|
| 9.
|
Yen, C. L.,
Mar, M. H.,
and Zeisel, S. H.
(1999)
FASEB J.
13,
135-142[Abstract/Free Full Text]
|
| 10.
|
Yen, C. L.,
Mar, M. H.,
Meeker, R. B.,
Fernandes, A.,
and Zeisel, S. H.
(2001)
FASEB J.
15,
1704-1710[Abstract/Free Full Text]
|
| 11.
|
Baburina, I.,
and Jackowski, S.
(1998)
J. Biol. Chem.
273,
2169-2173[Abstract/Free Full Text]
|
| 12.
|
Miquel, K.,
Pradines, A.,
Terce, F.,
Selmi, S.,
and Favre, G.
(1998)
J. Biol. Chem.
273,
26179-26186[Abstract/Free Full Text]
|
| 13.
|
Clement, J. M.,
and Kent, C.
(1999)
Biochem. Biophys. Res. Commun.
257,
643-650[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Zoeller, R. A.,
Layne, M. D.,
and Modest, E. J.
(1995)
J. Lipid Res.
36,
1866-1875[Abstract]
|
| 15.
|
Bazill, G. W.,
and Dexter, T. M.
(1990)
Cancer Res.
50,
7505-7512[Abstract/Free Full Text]
|
| 16.
|
Kabarowski, J. H.,
Zhu, K., Le, L. Q.,
Witte, O. N.,
and Xu, Y.
(2001)
Science
293,
702-705[Abstract/Free Full Text]
|
| 17.
| Ruiter, G. A., Verheij, M., Zerp, S., Moolenaar, W. H., and
van Blitterswijk, W. J. (2002) Int. J. Cancer, in
press
|
| 18.
|
Kelley, E. E.,
Modest, E. J.,
and Burns, C. P.
(1993)
Biochem. Pharmacol.
45,
2435-2439[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Small, G. W.,
Strum, J. C.,
and Daniel, L. W.
(1997)
Lipids
32,
715-723[Medline]
[Order article via Infotrieve]
|
| 20.
|
Simons, K.,
and Toomre, D.
(2000)
Nat. Rev. Mol. Cell. Biol.
1,
31-39[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Smets, L. A.,
Van Rooij, H.,
and Salomons, G. S.
(1999)
Apoptosis
4,
419-427[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Nicoletti, I.,
Migliorati, G.,
Pagliacci, M. C.,
Grignani, F.,
and Riccardi, C.
(1991)
J. Immunol. Methods
139,
271-279[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Lisanti, M. P.,
Tang, Z.,
Scherer, P. E.,
and Sargiacomo, M.
(1995)
Methods Enzymol.
250,
655-668[Medline]
[Order article via Infotrieve]
|
| 24.
|
Boggs, K. P.,
Rock, C. O.,
and Jackowski, S.
(1995)
J. Biol. Chem.
270,
11612-11618[Abstract/Free Full Text]
|
| 25.
|
van Meer, G.,
Stelzer, E. H.,
Wijnaendts-van-Resandt, R. W.,
and Simons, K.
(1987)
J. Cell Biol.
105,
1623-1635[Abstract/Free Full Text]
|
| 26.
|
Sprong, H.,
van Der, S. P.,
and van Meer, G.
(2001)
Nat. Rev. Mol. Cell. Biol.
2,
504-513[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Tartakoff, A. M.
(1983)
Cell
32,
1026-1028[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Ikonen, E.
(2001)
Curr. Opin. Cell Biol.
13,
470-477[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Puri, V.,
Watanabe, R.,
Singh, R. D.,
Dominguez, M.,
Brown, J. C.,
Wheatley, C. L.,
Marks, D. L.,
and Pagano, R. E.
(2001)
J. Cell Biol.
154,
535-547[Abstract/Free Full Text]
|
| 30.
|
Nichols, B. J.,
and Lippincott-Schwartz, J.
(2001)
Trends Cell Biol.
11,
406-412[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Mattjus, P.,
Bittman, R.,
and Slotte, J. P.
(1996)
Langmuir
12,
1284-1290[CrossRef]
|
| 32.
|
van Blitterswijk, W. J.,
van der Meer, B. W.,
and Hilkmann, H.
(1987)
Biochemistry
26,
1746-1756[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Tepper, A. D.,
Ruurs, P.,
Wiedmer, T.,
Sims, P. J.,
Borst, J.,
and van Blitterswijk, W. J.
(2000)
J. Cell Biol.
150,
155-164[Abstract/Free Full Text]
|
| 34.
|
van der Bliek, A. M.,
and Meyerowitz, E. M.
(1991)
Nature
351,
411-414[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Oh, P.,
McIntosh, D. P.,
and Schnitzer, J. E.
(1998)
J. Cell Biol.
141,
101-114[Abstract/Free Full Text]
|
| 36.
|
Henley, J. R.,
Krueger, E. W.,
Oswald, B. J.,
and McNiven, M. A.
(1998)
J. Cell Biol.
141,
85-99[Abstract/Free Full Text]
|
| 37.
|
Pagano, R. E.,
and Sleight, R. G.
(1985)
Science
229,
1051-1057[Abstract/Free Full Text]
|
| 38.
|
Hao, M.,
and Maxfield, F. R.
(2000)
J. Biol. Chem.
275,
15279-15286[Abstract/Free Full Text]
|
| 39.
|
Parton, R. G.
(1996)
Curr. Opin. Cell Biol.
8,
542-548[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Orlandi, P. A.,
and Fishman, P. H.
(1998)
J. Cell Biol.
141,
905-915[Abstract/Free Full Text]
|
| 41.
|
Torgersen, M. L.,
Skretting, G.,
van Deurs, B.,
and Sandvig, K.
(2001)
J. Cell Sci.
114,
3737-3747[Abstract/Free Full Text]
|
| 42.
|
Lamaze, C.,
Dujeancourt, A.,
Baba, T., Lo, C. G.,
Benmerah, A.,
and Dautry-Varsat, A.
(2001)
Mol. Cell
7,
661-671[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Rosenberger, C. M.,
Brumell, J. H.,
and Finlay, B. B.
(2000)
Curr. Biol.
10,
R823-R825[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Pelkmans, L.,
Kartenbeck, J.,
and Helenius, A.
(2001)
Nat. Cell Biol.
3,
473-483[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Gagescu, R.,
Demaurex, N.,
Parton, R. G.,
Hunziker, W.,
Huber, L. A.,
and Gruenberg, J.
(2000)
Mol. Biol. Cell
11,
2775-2791[Abstract/Free Full Text]
|
| 46.
|
van Blitterswijk, W. J.,
Van der Luit, A. H.,
Caan, W.,
Verheij, M.,
and Borst, J.
(2001)
Biochem. Soc. Trans.
29,
819-824
|
| 47.
|
van Blitterswijk, W. J.,
Schaap, D.,
and van der Bend, R. L.
(1994)
Curr. Top. Membr.
40,
413-437
|
| 48.
|
Exton, J. H.
(1994)
Biochim. Biophys. Acta
1212,
26-42[Medline]
[Order article via Infotrieve]
|
| 49.
|
Levade, T.,
and Jaffrezou, J. P.
(1999)
Biochim. Biophys. Acta
1438,
1-17[Medline]
[Order article via Infotrieve]
|
| 50.
|
Bankaitis, V. A.
(2002)
Science
295,
290-291[Abstract/Free Full Text]
|
| 51.
|
Roth, M. G.
(1999)
Trends Cell Biol.
9,
174-179[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Di Fiore, P. P.,
and De Camilli, P.
(2001)
Cell
106,
1-4[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
McMaster, C. R.
(2001)
Biochem. Cell Biol.
79,
681-692[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
van Dijk, M. C.,
Postma, F.,
Hilkmann, H.,
Jalink, K.,
van Blitterswijk, W. J.,
and Moolenaar, W. H.
(1998)
Curr. Biol.
8,
386-392[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. K. Jackson, W. Abate, J. Parton, S. Jones, and J. L. Harwood
Lysophospholipid metabolism facilitates Toll-like receptor 4 membrane translocation to regulate the inflammatory response
J. Leukoc. Biol.,
July 1, 2008;
84(1):
86 - 92.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Nieto-Miguel, R. I. Fonteriz, L. Vay, C. Gajate, S. Lopez-Hernandez, and F. Mollinedo
Endoplasmic Reticulum Stress in the Proapoptotic Action of Edelfosine in Solid Tumor Cells
Cancer Res.,
November 1, 2007;
67(21):
10368 - 10378.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H. van der Luit, S. R. Vink, J. B. Klarenbeek, D. Perrissoud, E. Solary, M. Verheij, and W. J. van Blitterswijk
A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells
Mol. Cancer Ther.,
August 1, 2007;
6(8):
2337 - 2345.
[Abstract]
[Full Text]
[PDF]
|
 |
|